Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ajai Chari

Showing results (1-10 of 207) with videos related to

Pageof 21
Sort By:
BMC Cancer|December 5, 2014
Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoringAjai Chari, Daher Hajje
Current Hematologic Malignancy Reports|February 29, 2016
Diagnostic Advances in Multiple MyelomaKevin Barley, Ajai Chari
Cell Cycle (Georgetown, Tex.)|June 23, 2018
Imipridone ONC201: combination therapy in hematologic malignanciesAjai Chari, Bart Barlogie
Clinical Lymphoma, Myeloma & Leukemia|October 23, 2012
Erectile dysfunction associated with bortezomib treatment in a patient with multiple myeloma and amyloidosisHadass Pri-Chen, Ajai Chari
Hematology/Oncology Clinics of North America|January 23, 2024
Role of Consolidation and MaintenanceAnupama D Kumar, Ajai Chari
Clinical Advances in Hematology & Oncology : H&O|February 13, 2014
Risk stratification in multiple myeloma, part 2: the significance of genetic risk factors in the era of currently available therapiesNoa Biran, Sundar Jagannath, Ajai Chari
Targeted Oncology|October 19, 2020
Targeting Nuclear Export Proteins in Multiple Myeloma TherapyNicholas Theodoropoulos, Guido Lancman, Ajai Chari
Biologics : Targets & Therapy|December 1, 2010
Proteasome inhibition and its therapeutic potential in multiple myelomaAjai Chari, Amitabha Mazumder, Sundar Jagannath
Hematology. American Society of Hematology. Education Program|December 4, 2020
Bispecifics, trispecifics, and other novel immune treatments in myelomaGuido Lancman, Joshua Richter, Ajai Chari
Clinical Advances in Hematology & Oncology : H&O|February 13, 2014
Risk stratification in multiple myeloma, part 1: characterization of high-risk diseaseNoa Biran, Sundar Jagannath, Ajai Chari
Pageof 21

Showing results (1-10 of 207) with videos related to

Sort By:
Pageof 21
BMC Cancer|December 5, 2014
Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoringAjai Chari, Daher Hajje
Current Hematologic Malignancy Reports|February 29, 2016
Diagnostic Advances in Multiple MyelomaKevin Barley, Ajai Chari
Cell Cycle (Georgetown, Tex.)|June 23, 2018
Imipridone ONC201: combination therapy in hematologic malignanciesAjai Chari, Bart Barlogie
Clinical Lymphoma, Myeloma & Leukemia|October 23, 2012
Erectile dysfunction associated with bortezomib treatment in a patient with multiple myeloma and amyloidosisHadass Pri-Chen, Ajai Chari
Hematology/Oncology Clinics of North America|January 23, 2024
Role of Consolidation and MaintenanceAnupama D Kumar, Ajai Chari
Clinical Advances in Hematology & Oncology : H&O|February 13, 2014
Risk stratification in multiple myeloma, part 2: the significance of genetic risk factors in the era of currently available therapiesNoa Biran, Sundar Jagannath, Ajai Chari
Targeted Oncology|October 19, 2020
Targeting Nuclear Export Proteins in Multiple Myeloma TherapyNicholas Theodoropoulos, Guido Lancman, Ajai Chari
Biologics : Targets & Therapy|December 1, 2010
Proteasome inhibition and its therapeutic potential in multiple myelomaAjai Chari, Amitabha Mazumder, Sundar Jagannath
Hematology. American Society of Hematology. Education Program|December 4, 2020
Bispecifics, trispecifics, and other novel immune treatments in myelomaGuido Lancman, Joshua Richter, Ajai Chari
Clinical Advances in Hematology & Oncology : H&O|February 13, 2014
Risk stratification in multiple myeloma, part 1: characterization of high-risk diseaseNoa Biran, Sundar Jagannath, Ajai Chari
Pageof 21